NYSE:GSK 4 May 2026 - 15 May 2026

GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view
··

GSK trades close to analyst target after Nuvalent deal

GSK plc traded a bit lower in late London hours on Monday, with the bigger focus for investors on valuation rather than the minor decline. Shares showed a sell price of 1,980.50p and a buy price at 1,981.00p as of 11:46 BST, down 0.13%. The FTSE 100 was down too. Shares are now close to the median analyst target. Investors Chronicle data shows 18 analysts have a median 12-month target of 1,980p, with estimates ranging from 2,750p down to 1,455p. The stock is up 40.91% over the past year, which suggests to some the easier part of the re-rating is probably over.
June 29, 2026
GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial
·····

GSK Plc Dividend Date Today: Why Its 2026 Payout Is Back in Focus

GSK’s U.S.-listed American depositary shares go ex-dividend on Friday, putting the British drugmaker’s next payout into live market focus. The company’s calendar lists May 15 as the ADS ex-dividend and record date for its first-quarter dividend, with payment due July 9; a market notice this week also flagged GSK among stocks going ex-dividend on May 15. Ex-dividend means new buyers after the cut-off no longer receive the next declared payout. That matters now because GSK is trying to keep its income case steady while asking investors to look harder at new drugs, not just the legacy strength of HIV medicines and vaccines.
May 15, 2026
GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead
····

GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead

Glaxo Group Limited, under the GSK Group umbrella, secured a Bombay High Court decision this day requiring Shreya Life Sciences Private Limited to cancel its registration of the Paxil trademark in India—a notable brand victory for GSK plc and its popular medicine. The dispute focused on Shreya’s lack of use of the mark in actual pharmaceutical products. The court's decision lands at a time when GSK faces scrutiny over whether new CEO Luke Miels can defend sales, speed up drug development, and handle looming patent cliffs. Shares dropped last week despite a first-quarter beat—traders picked over the numbers and flagged issues beneath the surface. “Quality concerns around the earnings beat,” Verso Investment Management analyst James Eugene noted, pointing to non-recurring
May 4, 2026